Surrozen's President & CEO, Craig Parker, discusses how the expertise, resources and flexibility of Lonza have been fundamental in advancing its novel and complex bispecific antibody candidates that target the WNT pathway.

You may also be interested in:
Mammalian
Cell Line Development
Clinical Supply Services
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
Webinar (on-demand)
Outsourced Pharma Capacity Update - February 2025
Explore Lonza Biologics' end-to-end Drug Product capabilities along the full life cycle, seamlessly...
CDMO Notes Blog post
A Faster Path to the Clinic: Accelerating Biologics Development with Integrated Solutions
How Lonza’s team are helping to revolutionise the path to Biologics INDs, with an accelerated...
Podcast
A View On mRNA Encapsulation (S04 E03)
In this episode, we are joined by three experts—Christoph Hein (Fraunhofer IPK), Bern-hard Bobusch...
Protein image
White paper
From Discovery to Patients: an Integrated Service for ADC Development by Lonza and Synaffix
This white paper provides an in-depth look at the development and challenges of antibody-drug...
Webinar (on-demand)
Charting a Successful CMC Journey for Your ADC Drug Product
Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their...
ADC vial with gradient background - close crop
Interview
Expert Q&A: Accelerate Your ADC Journey
Filling the Need for Integrated Bioconjugate Solutions Antibody drug conjugates (ADCs) are...
KC Video thumbnail
Video
mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence
Discover how our team, with its impressive mRNA/LNP track record, can help you progress your...
Mammalian Biologics Drug Substance Manufacture MC1
Article
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be...
Bispecific
Podcast
A View On Antibody-Based Therapies (S04 E02)
In this episode, we are joined by Ronnie Wei, Head of Biologics Discovery and Devel-opment at ModeX...
Webinar (on-demand)
Early Preclinical Development of mRNA/LNP Projects, Transitioning Successfully to cGMP...
View our on-demand webinar exploring the development steps that lead to an mRNA construct optimized...
Webinar (on-demand)
Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins
Many of today’s expression platforms for recombinant protein production have been optimised for the...
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Webinar (on-demand)
Integrating a High Sensitivity Immunopeptidomics (MAPPs) Assay in Preclinical Immunogenicity Risk...
Immunogenicity poses a critical risk to all biologics, including monoclonal antibodies, ADCs,...